Evidence map›Paper›PMID 32979106›Full record

Trial reportMedical oncology (Northwood, London, England)2020

A phase I/II study of docetaxel in combination with pegylated liposomal doxorubicin in metastatic castration-resistant prostate cancer.

Damian A Laber, Jennifer Eatrides, Michael V Jaglal, Mintallah Haider, Nathan Visweshwar, Ankita Patel

Abstract readClinical Trial, Phase IClinical Trial, Phase II
PubMed Publisher
In one paragraph

Trial report in Medical oncology (Northwood, London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Damian A LaberSection of Satellite Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. Damian.Laber@moffitt.org.ORCID http://orcid.org/0000-0003-1041-4429
Jennifer EatridesSection of Satellite Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Michael V JaglalSection of Satellite Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Mintallah HaiderSection of Satellite Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Nathan VisweshwarDivision of Hematology/Oncology, Department of Medicine, Morsani School of Medicine, University of South Florida, Tampa, FL, USA.
Ankita PatelSection of Satellite Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
University of South Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Taxanes and anthracyclines have been among the best-studied chemotherapy classes in castration-resistant prostate cancer (CRPC). Docetaxel (D) 75 mg/m

Indexed as

AdenocarcinomaAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsDocetaxelDoxorubicinHumansMaleMiddle AgedPolyethylene GlycolsProstatic Neoplasms, Castration-ResistantTreatment OutcomeDocetaxelDoxorubicinliposomal doxorubicinPolyethylene GlycolsCastration-resistant prostate cancerDocetaxelDoxorubicinPhase 2 clinical trialPolyethylene glycol-coated liposome

Identifiers

PMID32979106
OpenAlexW3087938960

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.